Aquestive Therapeutics announced positive human factors and pharmacokinetic study results for its severe allergy treatment, Anaphylm, addressing prior FDA concerns. This significantly strengthens their position for an upcoming New Drug Application resubmission, potentially leading to market approval and substantial revenue growth.
Aquestive Therapeutics (AQST) has reported successful human factors and pharmacokinetic studies for Anaphylm, their severe allergy treatment. These studies directly address the issues raised in a previous FDA Complete Response Letter, particularly concerning packaging, instructions, and administration. The positive results, including significant improvements in ease of use and effective drug delivery even with minor misplacement, substantially de-risk the upcoming New Drug Application resubmission planned for Q3 2026. This development is a major positive catalyst for AQST, as successful FDA approval would open up a significant market opportunity for a novel, convenient treatment for anaphylaxis, driving long-term growth and potentially increasing short-term investor confidence.